Product Information
RIVASTIGMINE 13.3 MG/24HR PTCH is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $1.8036 per EA under NDC 70710119807. Its NADAC has been published 370 times since Jul 24, 2019.
FDA first approved this application on Mar 4, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
13.3 mg/24h
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710119807
Classification
Generic
Dosage Form
PATCH, EXTENDED RELEASE
Route
TRANSDERMAL
Effective Date
8/19/2026
Active Ingredients
RIVASTIGMINEApproval Type
Generic (ANDA)
FDA Application
ANDA206318FDA Approved
3/4/2019
TE Code
AB
On Market Since
3/6/2019
Pharmacological Classes
Price Statistics
The NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has been published 370 times since Jul 24, 2019, and over the history we have for it it has declined 66.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8036 per EA |
|---|---|
| All-time high | $5.3640 (Aug 14, 2019) |
| All-time low | $1.6436 (Apr 17, 2024) |
| 52-week high | $2.0633 |
| 52-week low | $1.8036 |
| Median price | $2.5247 |
| Average price | $2.8006 |
| Largest weekly change | -33.3% (Apr 17, 2024) |
| Weeks tracked | 370 |
| Tracking since | Jul 24, 2019 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of RIVASTIGMINE 13.3 MG/24HR PTCH?
The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 13.3 MG/24HR PTCH, manufactured by Zydus Pharmaceuticals (USA) Inc., is $1.8036 per EA (NDC 70710119807), effective Aug 19, 2026.
How has the price of RIVASTIGMINE 13.3 MG/24HR PTCH changed over time?
Over the history we have for it, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has declined 66.4%. It has been tracked across 370 weekly CMS publications since Jul 24, 2019.
What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 13.3 MG/24HR PTCH?
Since Jul 24, 2019, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has ranged from a low of $1.6436 (Apr 17, 2024) to a high of $5.3640 (Aug 14, 2019), with a median of $2.5247 per EA.
Are there cheaper alternatives to RIVASTIGMINE 13.3 MG/24HR PTCH?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 13.3 MG/24HR PTCH in a comparable dosage form, but none are currently priced below it.
Who manufactures RIVASTIGMINE 13.3 MG/24HR PTCH?
RIVASTIGMINE 13.3 MG/24HR PTCH (NDC 70710119807) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.